New drug combo aims to stop aggressive breast cancer from returning
NCT ID NCT07622836
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study is testing whether adding an immunotherapy drug called QL1706 to standard chemotherapy after surgery can help prevent high-risk triple-negative breast cancer from coming back. About 59 women with this aggressive cancer type will receive the combination treatment, followed by maintenance QL1706 alone. The main goal is to see how many women remain cancer-free three years later.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- QL1706 (a combination of two antibodies, Aipaluoli and tovorilimab) plus AC-T chemotherapy
- What this could lead to
- If successful, this could offer a more effective post-surgery treatment option for people with high-risk triple-negative breast cancer, potentially reducing the chance of the cancer coming back.
- What could go wrong
- This is a small, early-phase (Phase II) trial with only 59 participants, so results may not apply to everyone. The treatment combines chemotherapy with an immunotherapy drug, which can cause significant side effects, and it's not yet known if it will improve long-term survival.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADJUVANT THERAPY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The First Affiliated Hospital of Nanjing Medical University
RECRUITINGNanjing, Jiangsu, 210000, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can immunotherapy outperform chemo after stomach cancer surgery?
- Can an immune booster after lung cancer surgery keep the disease at bay?
- Could a pill after surgery keep early lung cancer from coming back?
- Promising new combo targets hard-to-treat breast cancer brain tumors
- AI model may personalize liver cancer care after surgery
- Last-Resort drug access opens for aggressive breast cancer patients